- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Nasdaq Stockholm AB: New last trading date in paid subscription units issued by Diagonal Bio AB | 145 | GlobeNewswire | At the request of Diagonal Bio AB, the last trading day in Diagonal Bio AB's
paid subscription shares will be changed on Nasdaq Stockholm from 10 May 2024
to 13 May 2024.
Short name: DIABIO... ► Artikel lesen | |
| Di | Diagonal Bio AB announces last day of trading in BTU and first day of trading in TO 1 | 1 | Cision News | ||
| 25.04. | Nasdaq Stockholm AB: The observation status for Diagonal Bio AB is removed | 293 | GlobeNewswire | On February 5, 2024, the shares in Diagonal Bio AB (the "Company") were given
observation status with reference to substantial uncertainty regarding the
issuer or the pricing of its financial instruments.... ► Artikel lesen | |
| 24.04. | Diagonal Bio AB announces outcome of rights issue | 1 | Cision News | ||
| 16.04. | Diagonal Bio AB publish - White paper | 1 | Cision News | ||
| 08.04. | The subscription period in Diagonal Bio AB rights issue commences today | 1 | Cision News | ||
| 05.04. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Diagonal Bio AB | 190 | GlobeNewswire | With effect from April 08, 2024, the unit rights in Diagonal Bio AB will be
traded on First North Growth Market. Trading will continue up until and
including April 17, 2024.
Instrument: Unit rights... ► Artikel lesen | |
| 05.04. | DIAGONAL BIO AB: Diagonal Bio announces successful pilot study results and extended partnership with Hørsholm Veterinary Clinic | 2 | Cision News | ||
| 03.04. | Diagonal Bio AB publishes a prospectus because of upcoming rights issue | 1 | Cision News | ||
| 02.04. | Diagonal Bio AB: Bulletin from the Extraordinary General Meeting on Tuesday 2[nd] of April in Diagonal Bio AB | 63 | GlobeNewswire (Europe) | Today, 2nd April 2024, an Extraordinary General Meeting was held in Diagonal Bio AB, reg. no. 559248-8984. Below is a summary of the resolutions passed. All resolutions were passed with the required... ► Artikel lesen | |
| 02.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.04.2024 | 282 | Xetra Newsboard | Das Instrument 7ZO SE0017486426 TENDO AB EQUITY wird cum Kapitalmassnahme gehandelt am 02.04.2024 und ex Kapitalmassnahme am 03.04.2024 The instrument 7ZO SE0017486426 TENDO AB EQUITY is traded cum... ► Artikel lesen | |
| 28.02. | Notice to attend the extraordinary general meeting of Diagonal Bio AB | 1 | Cision News | ||
| 28.02. | DIAGONAL BIO AB: The Board of Directors decides on a preferential rights issue of units in order to finance future development | 1 | Cision News | ||
| 28.02. | Diagonal Bio AB: Diagonal Bio appoints Karin Wehlin as new CEO | 28 | GlobeNewswire (Europe) | Diagonal Bio AB (publ.) ("Diagonal Bio" or "the Company") is pleased to announce that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin... ► Artikel lesen | |
| 28.02. | Diagonal Bio AB: Diagonal Bio AB Year-end Report 2023 | 33 | GlobeNewswire (Europe) | "Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive... ► Artikel lesen | |
| 05.02. | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status (58/24) | 227 | GlobeNewswire | On February 2, 2024, Diagonal Bio AB (the "Company") disclosed a press release
with information on the Company's financial situation.
The rules of First North Growth Market state that a listed company... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 22,650 | -0,48 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress | Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,657 | +3,54 % | Pacific Biosciences Of California, Inc. Q1 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for first quarter that decreased from the same period last year but beat the Street estimates.The company's... ► Artikel lesen | |
| CENTOGENE | 0,354 | -2,35 % | Centogene NV: CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients | CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,773 | -7,03 % | atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights | Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003... ► Artikel lesen | |
| BIOMERIEUX | 100,50 | +1,21 % | Barclays starts Biomerieux at 'overweight,' notes smoother growth among peers | ||
| CYCLACEL | 2,100 | -1,87 % | Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results | ||
| SYROS PHARMACEUTICALS | 4,620 | -4,55 % | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies... ► Artikel lesen | |
| GENUS | 21,400 | 0,00 % | Dividendenbekanntmachungen (29.02.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,14 USD 0,1291 EUR AGNICO EAGLE MINES LIMITED CA0084741085 0,4 USD 0,369 EUR ALLIANCE... ► Artikel lesen | |
| ATRECA | 0,155 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.03.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 28.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.03.2024ISIN NameGB00BZ2JBG28 REACT... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 2,260 | +0,89 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 21,600 | -10,00 % | AnaptysBio, Inc.: Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update | Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase... ► Artikel lesen | |
| ABIONYX PHARMA | 0,966 | -1,23 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MEIRAGTX | 4,720 | +0,43 % | MeiraGTx GAAP EPS of -$0.32, revenue of $0.69M | ||
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA 7ME: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMETABOLIC EXPLORER... ► Artikel lesen | |
| AKESO | 5,900 | +2,61 % | Akeso, Inc.: Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR | SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,007 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
